Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial

JAMA Psychiatry. 2021 Mar 1;78(3):335-337. doi: 10.1001/jamapsychiatry.2020.3567.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cannabidiol / administration & dosage
  • Cannabidiol / urine*
  • Cannabinoid Receptor Agonists / administration & dosage
  • Cannabinoid Receptor Agonists / urine*
  • Dronabinol / administration & dosage
  • Dronabinol / urine*
  • Female
  • Humans
  • Male
  • Substance Abuse Detection*
  • Urinalysis*

Substances

  • Cannabinoid Receptor Agonists
  • Cannabidiol
  • Dronabinol